Cure8 research brief
For people with UC who do not respond to tacrolimus, adding infliximab may induce remission and reduce the short-term need for colectomy. The findings point to a potential rescue strategy and an option to transition to infliximab maintenance.
Adults with refractory ulcerative colitis, patients on or considering biologic therapy, and gastroenterologists treating steroid- or calcineurin-resistant UC.
The report describes 21 patients with moderate-to-severe UC who did not achieve remission on tacrolimus alone; infliximab was added (dual therapy). About 38% achieved clinical remission by 8 weeks and around 62% were colectomy-free at one year after starting dual therapy.
When tacrolimus was stopped and infliximab maintenance continued, most patients who had achieved remission remained relapse-free at one year. Adverse events were reported but described as infrequent; examples in the abstract include acute kidney injury, infections, and skin rash.
This is an abstract-level report from a journal article describing a small, single-center series; it suggests dual therapy could be an option for refractory cases but is not definitive evidence.
This is an abstract-level clinical series (21 patients) from a single center spanning 2011–2024. Results are preliminary and based on a small cohort; larger controlled studies are needed to confirm safety and effectiveness.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
Patients with UC who fail both anti-TNF and JAK inhibitor therapies have limited options. This report suggests tacrolimus can be used as a short-term bridge or in combination to reach another maintenance drug, with many...
For patients and clinicians facing steroid- and infliximab-refractory acute severe ulcerative colitis, upadacitinib may be a third-line medical option that can produce rapid symptom and CRP improvement and allow some...
